Within this subgroup analysis from Arbeitsgemeinschaft Internistische Onkologie-pancreatic cancer ( AIO-PK@ ) , no evidence supporting the use of hENT@ as a predictive biomarker for gemcitabine efficacy in patients with advanced pancreatic cancer was found .